RESEARCH USE ONLY
glp-1
This topic hub features research reagents related to GLP-1 analogs, which are involved in glucose metabolism and insulin secretion regulation. Within this collection, readers will discover monographs on compounds such as Retatrutide, Semaglutide, and Tirzepatide, each with unique properties and mechanisms of action supported by published research. The compounds are presented in terms of their class, purity, and research context.
In this topic
Incretin AgonistsRetatrutideRetatrutide (LY3437943) is a synthetic single-molecule triple agonist of the GIP, GLP-1 and glucagon receptors studied in metabolic research on obesity and type 2 diabetes.Incretin AgonistsGLP-1, GIP and glucagon: three incretin axesEducational primer mapping GLP-1 mono, dual GIP/GLP-1, and triple agonist axes to catalog molecules. Research use only.Incretin AgonistsLiraglutideLiraglutide (Victoza/Saxenda) is an acylated, once-daily GLP-1 analogue. Mechanism of action, pharmacokinetics, and key clinical data with verified sources.Incretin AgonistsSemaglutideSemaglutide is a long-acting acylated analogue of glucagon-like peptide-1, a GLP-1 receptor agonist that has been the subject of extensive preclinical and clinical research on glycaemic control and body-weight regulation. This overview is strictly scientific and reference in nature.Incretin AgonistsTirzepatideTirzepatide (LY3298176) is a dual GIP/GLP-1 receptor agonist studied for metabolic regulation. Neutral reference: mechanism, dosing context, and related GLP-1 catalog links.